EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers

Kristen R Ibanez iD, Tzu-Ting Huang iD, Jung-Min Lee

Cells · 19.06.2024 · 13 (12) · 1064

DOI: 10.3390/cells13121064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 19.06.2024. Verfasst von Kristen R Ibanez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, Drug Resistance, Neoplasm, Phosphoinositide-3 Kinase Inhibitors, Signal Transduction. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Intramural Research Program of Center for Cancer Research, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PI3K signaling pathway plays an essential role in cancer cell proliferation and survival. PI3K pathway inhibitors are now FDA-approved as a single agent treatment or in combination for solid tumors such as renal cell carcinoma or breast cancer. However, despite the high prevalence of PI3K pathway alterations in gynecological cancers and promising preclinical activity in endometrial and ovarian cancer models, PI3K pathway inhibitors showed limited clinical activity in gynecological cancers. In this review, we provide an overview on resistance mechanisms against PI3K pathway inhibitors that limit their use in gynecological malignancies, including genetic alterations that reactivate the PI3K pathway such as PIK3CA mutations and PTEN loss, compensatory signaling pathway activation, and feedback loops causing the reactivation of the PI3K signaling pathway. We also discuss the successes and limitations of recent clinical trials aiming to address such resistance mechanisms through combination therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genital Neoplasms, FemaleDrug Resistance, NeoplasmPhosphoinositide-3 Kinase InhibitorsSignal TransductionHumansFemalePhosphatidylinositol 3-KinasesProtein Kinase InhibitorsAnimals

Stichwörter der Autor:innen

PI3K/AKT/mTOR inhibitorscombination treatmentgynecological cancerresistance mechanismstargeted therapy

Substanzen

Phosphoinositide-3 Kinase InhibitorsPhosphatidylinositol 3-KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Kristen R Ibanez, Tzu-Ting Huang

Förderung

  • NCI NIH HHS
  • Intramural Research Program of Center for Cancer Research, National Cancer Institute, National Institutes of Health

Zitieren

APA

Ibanez, K. R., Huang, T. T., & Lee, J. M. (2024). Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers. Cells, 13(12), 1064. https://doi.org/10.3390/cells13121064

Vancouver

Ibanez KR, Huang TT, Lee JM. Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers. Cells. 2024;13(12):1064. doi:10.3390/cells13121064

BibTeX
@article{Ibanez2024,
  author = {Ibanez, Kristen R and Huang, Tzu-Ting and Lee, Jung-Min},
  title = {Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {12},
  pages = {1064},
  doi = {10.3390/cells13121064}
}
Kostenlos starten →